SNDX (Syndax Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by SNDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | Michael A Metzger | Chief Executive Officer | MIXED | — | — |
| 2026-06-12 | Nicholas A.J. Botwood | Head of R&D, CMO | MIXED | — | — |
| 2026-06-02 | Michael A Metzger | Chief Executive Officer | Sell | — | — |
| 2026-06-02 | Keith A. Goldan | Chief Financial Officer | Sell | — | — |
| 2026-02-10 | Keith A. Goldan | Chief Financial Officer | Sell | — | — |
| 2026-02-10 | Michael A Metzger | Chief Executive Officer | Sell | — | — |
| 2026-02-06 | Pierre Legault | Director | A | — | — |
| 2026-02-06 | Dennis Podlesak | Director | A | — | — |
| 2026-02-06 | Keith Katkin | Director | A | — | — |
| 2026-02-06 | Aleksandra Rizo | Director | A | — | — |
| 2026-02-06 | Jennifer Jarrett | Director | A | — | — |
| 2026-02-06 | Nicholas A.J. Botwood | Head of R&D, CMO | A | — | — |
| 2026-02-06 | Martin H. Huber Jr. | Director | A | — | — |
| 2026-02-06 | Michael A Metzger | Chief Executive Officer | MIXED | — | — |
| 2026-02-06 | Keith A. Goldan | Chief Financial Officer | MIXED | — | — |
| 2025-12-01 | Keith A. Goldan | Chief Financial Officer | G | — | — |
| 2025-09-08 | Michael A Metzger | Chief Executive Officer | MIXED | — | — |
| 2025-08-18 | Dennis Podlesak | Director | MIXED | — | — |
| 2025-08-07 | Keith A. Goldan | Chief Financial Officer | J | — | — |
| 2025-07-18 | Michael A Metzger | Chief Executive Officer | Sell | — | — |
| 2025-07-18 | Keith A. Goldan | Chief Financial Officer | Sell | — | — |
| 2025-05-19 | Keith A. Goldan | Chief Financial Officer | Buy | — | — |
| 2025-05-19 | Martin H. Huber Jr. | Director | Buy | — | — |
| 2025-05-19 | Keith Katkin | Director | Buy | — | — |
| 2025-05-19 | Nicholas A.J. Botwood | Head of R&D, CMO | Buy | — | — |
| 2025-03-17 | Michael A Metzger | Chief Executive Officer | M | — | — |
| 2025-03-06 | Michael A Metzger | Chief Executive Officer | MIXED | — | — |
| 2025-02-12 | Keith A. Goldan | Chief Financial Officer | Sell | — | — |
| 2025-02-12 | Neil Gallagher | President, Head of R&D | Sell | — | — |
| 2025-02-12 | Michael A Metzger | Chief Executive Officer | Sell | — | — |
| 2025-02-07 | William Meury | Director | A | — | — |
| 2025-02-07 | Aleksandra Rizo | Director | A | — | — |
| 2025-02-07 | Martin H. Huber Jr. | Director | A | — | — |
| 2025-02-07 | Jennifer Jarrett | Director | A | — | — |
| 2025-02-07 | Keith Katkin | Director | A | — | — |
| 2025-02-07 | Keith A. Goldan | Chief Financial Officer | A | — | — |
| 2025-02-07 | Pierre Legault | Director | A | — | — |
| 2025-02-07 | Neil Gallagher | President, Head of R&D | A | — | — |
| 2025-02-07 | Dennis Podlesak | Director | A | — | — |
| 2025-02-07 | Michael A Metzger | Chief Executive Officer | A | — | — |
| 2024-06-17 | Keith A. Goldan | Chief Financial Officer | Buy | — | — |
| 2024-05-16 | Aleksandra Rizo | Director | A | — | — |
| 2024-02-09 | Pierre Legault | Director | A | — | — |
| 2024-02-09 | William Meury | Director | A | — | — |
| 2024-02-09 | Jennifer Jarrett | Director | A | — | — |
| 2024-02-09 | Briggs Morrison | Director | A | — | — |
| 2024-02-09 | Dennis Podlesak | Director | A | — | — |
| 2024-02-09 | Neil Gallagher | President, Head of R&D | A | — | — |
| 2024-02-09 | Keith Katkin | Director | A | — | — |
| 2024-02-09 | Michael A Metzger | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,743,854 | — |
| — | 10%+ Owner | 1,138,210 | — |
| — | Director | 1,138,210 | — |
| — | 10%+ Owner | 761,062 | — |
| — | Director | 625,545 | — |
| — | Chief Executive Officer | 517,218 | — |
| — | Director | 239,763 | — |
| — | Chief Financial Officer | 139,252 | — |
| — | Director | 124,000 | — |
| — | Director | 114,000 | — |
| — | Director | 114,000 | — |
| — | Director | 103,000 | — |
| — | Head of R&D, CMO | 95,165 | — |
| — | Director | 90,000 | — |
| — | President, Head of R&D | 85,095 | — |
| — | — | 85,038 | — |
| — | Director | 49,000 | — |
| — | Director | 34,836 | — |
| — | Director | 32,000 | — |
| — | SVP, Chief Medical Officer | 23,280 | — |
| — | Director | 13,925 | — |
| — | 10%+ Owner | 5,641 | — |
| — | Chief Financial Officer | 5,616 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SNDX quote page; the site-wide leaderboard is on the insider transactions hub.